StockStory.org on MSN
DexCom (NASDAQ:DXCM) exceeds Q4 CY2025 expectations
Medical device company DexCom (NASDAQ:DXCM) announced in Q4 CY2025, with sales up 13.1% year on year to $1.26 billion. The ...
It has been about a month since the last earnings report for DexCom (DXCM). Shares have lost about 7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the ...
BofA keeps a Buy rating on DexCom (DXCM) with a $105 price target after Dexcom announced it received a warning letter from the FDA. Importantly, there is no expected impact to the timing of 15-day FDA ...
DexCom (NASDAQ: DXCM) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results